Artiva Biotherapeutics, Inc.

ARTV Nasdaq SEC CIK 1817241
Follow Artiva Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$28.8M −33.9% vs same quarter last year
EPS, diluted −$0.56 +36.4% vs same quarter last year
Operating cash flow −$28.4M −48.2% vs same quarter last year
Operating income −$32M −39.6% vs same quarter last year
Net income by quarter
−$16.1M
−$20.3M
−$21.3M
−$21.5M
−$20.8M
−$23.5M
−$25M
−$28.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$83.9M
FY24$251K−$65.4M
FY23$32.9M−$28.7M
FY22--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$79.3M
FY24−$55.7M
FY23−$50.7M
FY22-